Audio Seminars

Home | Contact Us | Newsletter | Usersclub | Books | Audio Seminars

All documents shown here are included in the seminar for instant download

Edwin Rivera
 Data Integrity and Fraud - An Other looming Crisis

Steve Wilson:
FDA Regulatory Perspective on Data integrity


Warning letters and Inspectional observations related to raw data and other electronic records

Labcompliance On-line Audio Seminar

This seminar has been recorded and is available on CD and for instant download. All reference material as listed below and more is available on a special seminar website. The website is regularly updated with most recent information. In case there are questions related to the topic, they can be submitted through a web form and will be answered by the speaker. For ordering info click here
To share this seminar info with your colleagues, click here

On-line Audio Seminar 373

Integrity of Laboratory Data for FDA/EU Compliance

Understand and implement data integrity through the entire data life cycle

Recorded, available with all reference material at any time

Order Button

FDA has found and reported about multiple cases where companies manipulated electronic laboratory records to bring out-of-specification results into specifications.  Since then FDA inspectors have focused during GLP, GCP and GMP inspections on  integrity of 'complete' laboratory records. FDA has trained inspectors to identify data falsification and recommended the same to industry QA departments and auditors. Just in the last three years FDA issued over 30 warning letters and 483 form inspectional observations related to electronic records. The industry is unsure how to comply with FDA inspection requirements. 

Key Questions are:

  • What are FDA requirements and inspection practices for laboratory data?
  • Why are there so many integrity violations?
  • How important is the new UK MHRA GMP Data Integrity Guideline
  • What are the most frequently found inspection deviations?
  • Can I delete the electronic records after I have printed and signed the  equivalent paper records?
  • FDA requires availability of 'complete' records, what does this mean?
  • How to define raw data?
  • What are the requirements for data integrity and security?
  • How to demonstrate data integrity and security?
  • Is e-audit trail still under enforcement discretion and what does this mean?
  • FDA and the Annex 11 require reviewing electronic audit trails. Who should to this, when and how should it be documented?
  • How important is risk assessment for managing laboratory data?
  • I scan paper print-outs and store PDF files in a data base - can I delete the paper records?
  • The new EU Annex 11 requires indicating changes of raw data on print-outs, how can we do this?
  • Should I be able to reprocess the reprocess electronic raw data and if so for how long?

How does the this audio seminar help:

Answers will be presented by Dr. Ludwig Huber in a new interactive audio seminar. During the seminar, the speaker will present strategies and give practical recommendations and case studies. After the seminar, an extensive list of reference material like SOPs, worksheets, templates and examples will help immediate and cost effective implementation of the principles and strategies.

During the interactive presentation you learn about:

  • Definitions of data integrity:  FDA, UK MHRA GMP Data Integrity Guideline
  • Ten key FDA/EU requirements for integrity and security of laboratory data
  • How FDA inspectors check integrity and security of data
  • Reasons for data integrity observations
  • The new UK MHRA GMP Data Integrity Guideline - Meaning and Key Points
  • Most frequent security and integrity issues: going through recent 483's, EIRs and warning letters?
  • Responding to FDA reports with root cause, corrective and preventive actions
  • The importance of limited access to 'individual users' rather than to groups
  • FDA compliant definition, acquisition, maintenance and archiving of raw data
  • Critical integrity and security issues during the entire life of laboratory data: from  data acquisition through evaluation to archiving
  • Examples how to ensure and document data integrity
  • Documenting changes of laboratory data: paper, hybrid systems, electronic
  • The importance of electronic audit trail to document data integrity
  • Review of electronic audit trail: who, what, when and how
  • Ensuring timely availability through validated back-up and archiving periods
  • Going through representative 10 case studies: FDA observations, complete responses to each observation, corrective actions and preventive actions

And for easy and instant implementation:
download 10+ documents from special seminar website

  • SOP: Integrity and Security of Electronic Laboratory Data
  • SOP: 21 CFR Part11 - Scope and Controls
  • SOP: Electronic Audit Trail - Specification, Implementation, Validation
  • SOP: Review of Electronic Audit Trail
  • SOP: Retention and Archiving of Electronic Records
  • SOP: Manual Reintegration of Chromatographic Peaks
  • Checklist: Security and Integrity of Electronic Laboratory Data
  • Checklist: Electronic Audit Trail
  • 10 Case studies: FDA observations, complete responses to each observation, corrective actions and preventive actions
  • FDA Presentation: Data Integrity and Fraud – Another Looming Crisis?
  • FDA Presentation:  Steve Wilson FDA Regulatory Perspective an Data integrity
  • Regulatory reference documents:
    - FDA Drug cGMP: Requirements for 'Complete' Laboratory Records
    - Requirements for Clinical Trial Records
  • Literature Reference papers.
    - Implementing 21 CFR Part 11 - Data Migration and Long Term Archiving for Ready Retrieval
  • 20+ Warning letters and Inspectional observations related to laboratory data integrity and security

Who should attend?

  • Everybody who creates, reviews and approves laboratory data
  • Pharmaceutical and Device Manufacturers
  • API Manufacturers
  • Contract Laboratory Organizations providing services for GxP compliance
  • Documentation professionals
  • QA/QC managers and personnel
  • IT professionals
  • Analysts and lab managers
  • Validation specialists
  • Training departments
  • Consultants

Date and time

Recorded seminar, available at any time with all reference material

How to order

Pick one of the options in the table that fits your needs.

Recorded seminar - Web Download

  • Multiple persons - single site
  • Learn at your desk, meet in a seminar or conference room or share the audio file and reference material at your site.
  • Order includes all reference material.

US$ 399.-
Order Now Button

Recorded seminar - CD

  • Get the CD in your mail
  • Order includes all reference material.

US$ 399.-
Order Now Button

Special offer for Labcompliance Usersclub Members
Recorded Seminar- CD or Web download.

  • Order includes all reference material.
  • for Usersclub information and registration, click here

US$ 299.-
Order Now Button

Please forward to your colleagues 

just click here

About audio seminars

Online audio seminars are presented over the phone. During the live presentation attendees can:

  1. Study the printed slide material
  2. Watch the slides on a computer
  3. Watch the slides on a video screen in a seminar room
  4. Ask questions through email and web form

About Dr. Ludwig Huber

Dr. Ludwig Huber is the editor and author of Labcompliance. He has been conducting over 300 web and audio or video based seminars since 15 years and and he has given multiple presentations mainly on GLP/GMP, 21 CFR Part 11 and Validation around the world. This included seminars, workshops and presentations for the US FDA, SFDA, KFDA, HSA, ISPE, PDA, PIC/S and several national health agencies.

Dr. Ludwig Huber is a frequent presenter at IVT conferences and has been awarded as the 'Presenter of the Year' out of 170 speakers. This photo is from IVT's conference on Network Qualification with Ludwig Huber as plenary speaker.

Dr. Huber has published several books related to validation and compliance, for example: Validation of Computerized Analytical and Networked Systems. He was or still is a member of several committees, e.g., of the GAMP® Special interest group (SIG) on Laboratory Computers, PDA Part 11 task force, IVT task force on network infrastructure qualification and the European Compliance Academy. He frequently visited FDA in Rockville, VA, and participated in panel discussions with FDA professionals. For feedback from attendees of seminars and  for other information on Dr. Ludwig Huber, click here.

Dr. Ludwig Huber in Panel Discussions with FDA Officials

George Smith, FDA's national Part11 expert, at a panel discussion with Ludwig Huber during an IVT conference

Smith and Huber discussed and answered questions about computer system validation and e-records.
Ludwig Huber (right) and John Murray, FDA's Computer Validation Expert, (left), speaking at the IVT Computer System Validation Conference.
Mr. Murray explined FDA'snext steps for Part 11

Ludwig Huber (right) in a panel discussion with FDA inspectors and directors:
 Dr. Robert C. Horan, B Erik Henrikson,Joseph Famulare,  and Nicholas Buhay,





The Feedbacks on the seminar has been received by e-mails. Labcompliance has permission to use the testimonials as references. Original e-mails are stored in the Labcompliance archive.

  1. Seminar: FDA's New Enforcement of 21 CFR Part 11
    The seminar did meet my expectations.  I always expect a wonderful seminar from Dr. Huber, and my expectations were once again met. A great time saver for me as I do not have time to look up recent 483s relating to Part 11 -- worth the time and cost.
    Ms. Diana Mayes, Manager of ABC Laboratories, USA
    (Ref T-1077)
  2. Seminar: Recent Warning Letters and 483's Related to Computer Validation and Part 11
    The seminar did exceed my expectations.  The presentation contains much more pertinent information than I had expected.
    Mr. Joachim Fehr, Stryker, CSV Specialist QA, Germany
    (Ref T-1076).
  3. Seminar: Understanding and Preparing for FDA's New Part 11 Inspection Program
    Feedback: The seminar did exceed my expectations.  The seminar is very useful as it contains a lot of information.
    Mr. Lucian Hirtie,  QS Manager, Labstat International ULC, Canada
    (Ref T-1082).
  4. Seminar: Understanding and Preparing for FDA's New Part 11 Inspection Program
    Feedback: The seminar did exceed my expectations.  Very informative presentation, and clearly presented . Dr Huber does an excellent presentation, well developed, and very informative, as usual.
    Mr. John Egoville,  Senior Compliance Auditor,  Computer Validation Group, TEVA Pharmaceuticals, USA
    (Ref T-1081)

  5. Seminar: FDA's New Enforcement of 21 CFR Part 11
    The seminar exceed my expectations.  Webinar was very informative to our current practice and will help us focus and stream line our process. I would recommend this seminar to everyone having the same responsibilities.
    Ms. Mike Robertson, QA Engineer at Energizer, USA
    (Ref T-1078).